• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP HIV AG/AB COMBO (CHIV); CHIV IMMUNOASSAY,

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP HIV AG/AB COMBO (CHIV); CHIV IMMUNOASSAY, Back to Search Results
Model Number N/A
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code No Known Impact Or Consequence To Patient (2692)
Date of Event 05/16/2018
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
The cause for the discordant advia centaur xp hiv ag/ab combo (chiv) results is unknown.Siemens is investigating.The instruction for use (ifu) under the limitations section states the following: "the calculated values for anti-hiv and/or p24 antigen in a given specimen as determined by assays from different manufacturers can vary due to differences in assay methods and reagent specificity.The results reported by the laboratory to the physician must include the identity of the assay used.Values obtained with different assay methods cannot be used interchangeably.The reported antibody level and/or p24 antigen cannot be correlated to an endpoint titer." "currently available assays for the detection of p24 antigen and/or antibodies to hiv-1 and/or hiv-2 may not detect all infected individuals.A negative test result does not exclude the possibility of exposure to or infection with hiv.Hiv antibodies and/or p24 antigen may be undetectable in some stages of the infection and in some clinical conditions." mdr 1219913-2018-00170, and mdr 1219913-2018-00171 were filed for repeat testing with serum and plasma samples on a different day, and mdr 1219913-2018-00175 was filed for a reorder result from a different day from the same patient.
 
Event or Problem Description
(b)(6) advia centaur xp hiv ag/ab combo (chiv) results were obtained on a patient, and the initial reported result was questioned by the physician.The patient was previously tested for (b)(6) by pcr, and the result was (b)(6).The physician ordered a second advia centaur xp chiv test, and the result was (b)(6).The customer performed replicate (x3) testing of different sample tube types from the same patient, and the results were (b)(6) on the advia centaur xp.The patient samples were sent out, tested on three alternate hiv test methods, and the results were all (b)(6).A corrected report was issued by the customer.There are no reports that patient treatment was altered or prescribed or adverse health consequences due to the discordant advia centaur xp chiv results.Mdr 1219913-2018-00170, and mdr 1219913-2018-00171 were filed for repeat testing with serum and plasma samples on a different day, and mdr 1219913-2018-00175 was filed for a reorder result from a different day from the same patient.
 
Additional Manufacturer Narrative
Siemens filed mdr on 06/15/2018 for an initial false non-reactive advia centaur xp hiv ag/ab combo (chiv) serum sample result.07/25/2018: additional information: the patient sample (same pcr reactive sample) was returned and tested by siemens.The sample was tested with the advia centaur hiv ag/ab combo (chiv), and hiv 1/0/2 enhanced (ehiv) test methods.Results of the investigations indicate that the patient sample may be a p24-antibody only sample.This patient sample contains high p24 ab and is undergoing monoclonal immunotherapy.The primary purpose of the advia centaur chiv assay is to aid in the diagnosis of hiv infection.Chiv is a combo assay, it only has the architecture to detect p24 antigen.The ehiv assay has the assay architecture for p24 antibody detection, and was able to detect (high reactive) antibody in the patient sample.Heterophilic antibodies was hypothesized as a possible cause of interference, however heterophilic blocking tube (hbt) was not able to block any possible interferents in this sample.Based on the information, siemens is unable to rule out a sample specific issue as the cause for the false negative chiv results.Returned sample test results: advia centaur chiv test method reagent lot: result (index), hbt result (index), 117142, 0.70 (non-reactive), 0.51 (non-reactive).Advia centaur ehiv test method: reagent lot: result 103233, assay range (high reactive).The advia centaur xp instruction for use (ifu) under the limitations section states the following: "currently available assays for the detection of p24 antigen and/or antibodies to hiv-1 and/or hiv-2 may not detect all infected individuals.A negative test result does not exclude the possibility of exposure to or infection with hiv.Hiv antibodies and/or p24 antigen may be undetectable in some stages of the infection and in some clinical conditions." the advia centaur xp instruction for use (ifu) under the interpretation of results section states the following: "results of this assay should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings." the instrument is performing within specification.No further evaluation of the device is required.Mdr 1219913-2018-00170, and mdr 1219913-2018-00171 were filed on 06/15/2018 for repeat testing with serum and plasma samples on a different day, and mdr 1219913-2018-00175 was filed on 06/15/2018 for a reorder result from a different day from the same patient.Mdr 1219913-2018-00170 supplemental report 1, mdr 1219913-2018-00171 supplemental report 1, and mdr 1219913-2018-00175 supplemental report 1 were filed on 08/15/2018 for additional information.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVIA CENTAUR XP HIV AG/AB COMBO (CHIV)
Common Device Name
CHIV IMMUNOASSAY,
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
511 benedict avenue
tarrytown NY 10591 5097
MDR Report Key7606976
Report Number1219913-2018-00169
Device Sequence Number16676596
Product Code MZF
UDI-Device Identifier00630414589749
UDI-Public00630414589749
Combination Product (Y/N)N
Initial Reporter StateDC
Initial Reporter CountryUS
PMA/510(K) Number
BP140103
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source health professional,user faci
Initial Reporter Occupation Health Professional
Type of Report Initial,Followup
Report Date (Section B) 08/15/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date10/04/2018
Device Model NumberN/A
Device Catalogue Number10696880
Device Lot Number117142
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Initial Date Received by Manufacturer 05/23/2018
Supplement Date Received by Manufacturer07/25/2018
Initial Report FDA Received Date06/15/2018
Supplement Report FDA Received Date08/15/2018
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
-
-